|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
13,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Shuttle Pharmaceuticals Holdings is a clinical stage pharmaceutical company utilizing its proprietary technology to develop therapies designed to cure cancers. Co. is developing a pipeline of products designed to address limitations of the existing cancer therapies as well as to extend to the new applications of radiation therapy (RT). Co.'s product candidates include Ropidoxuridine (IPdR), Extended Bio-availability IPdR, and a platform of histone deacetylase inhibitors (SP-1-161, SP-2-225 and SP-1-303). IPdR is Co.'s primary candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
7,078 |
7,078 |
32,232 |
| Total Sell Value |
$0 |
$3,279 |
$3,279 |
$43,650 |
| Total People Sold |
0 |
2 |
2 |
10 |
| Total Sell Transactions |
0 |
2 |
2 |
12 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vander Hoek Michael |
Chief Financial Officer |
• – – |
2024-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
103,852 |
|
- |
|
| Brown Milton |
Director |
– • – |
2023-12-13 |
4 |
S |
$0.46 |
$1,353 |
D/D |
(2,921) |
1,094,610 |
|
- |
|
| Jacobs Bette |
Director |
– • – |
2023-12-13 |
4 |
S |
$0.46 |
$1,926 |
D/D |
(4,157) |
27,064 |
|
- |
|
| Dritschilo Anatoly |
CEO and Chairman |
• • • |
2023-08-14 |
4 |
GA |
$0.00 |
$0 |
I/I |
2,100,000 |
2,100,000 |
|
- |
|
| Dritschilo Anatoly |
CEO and Chairman |
• • • |
2023-08-14 |
4 |
GD |
$0.00 |
$0 |
I/I |
2,100,000 |
1,104,407 |
|
- |
|
| Senanayake Chris |
Director |
– • – |
2022-12-29 |
4 |
S |
$1.61 |
$2,610 |
D/D |
(1,626) |
2,791 |
|
- |
|
| Richards Steven M |
Director |
– • – |
2022-12-29 |
4 |
S |
$1.61 |
$1,597 |
D/D |
(995) |
1,707 |
|
- |
|
| Brown Milton |
Director |
– • – |
2022-12-29 |
4 |
S |
$1.61 |
$1,597 |
D/D |
(995) |
1,072,531 |
|
- |
|
| Adkins William |
Former Director |
– – – |
2022-12-29 |
4 |
S |
$1.61 |
$1,597 |
D/D |
(995) |
184,071 |
|
- |
|
| Rich Tyvin |
Chief Medical Officer |
• – – |
2022-12-29 |
4 |
S |
$1.61 |
$2,269 |
D/D |
(1,414) |
2,429 |
|
- |
|
| Dritschilo Anatoly |
CEO and Chairman |
• • • |
2022-12-29 |
4 |
S |
$1.61 |
$13,437 |
D/D |
(8,372) |
1,085,200 |
|
- |
|
| Jacobs Bette |
Director |
– • – |
2022-12-29 |
4 |
S |
$1.61 |
$7,007 |
D/D |
(4,366) |
31,221 |
|
- |
|
| Jung Mira |
Chief Scientific Officer |
• – – |
2022-12-29 |
4 |
S |
$1.61 |
$526 |
D/D |
(328) |
1,071,388 |
|
- |
|
| Vander Hoek Michael |
Chief Financial Officer |
• – – |
2022-12-29 |
4 |
S |
$1.61 |
$3,600 |
D/D |
(2,243) |
3,852 |
|
- |
|
| Dritschilo Peter |
President and COO |
• – – |
2022-12-29 |
4 |
S |
$1.61 |
$6,131 |
D/D |
(3,820) |
6,560 |
|
- |
|
| Jacobs Bette |
Director |
– • – |
2022-10-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
35,587 |
|
- |
|
| Brown Milton |
Director |
– • – |
2022-08-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,073,526 |
|
- |
|
| Dritschilo Anatoly |
CEO and ChairmanOfficer |
• • • |
2022-08-29 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
1,093,572 |
|
- |
|
| Senanayake Chris |
Director |
– • – |
2022-08-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,843 |
|
- |
|
| Adkins William |
Director |
– • – |
2022-08-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
280,480 |
|
- |
|
| Jung Mira |
Chief Scientific OfficerOffice |
• – – |
2022-08-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,071,716 |
|
- |
|
| Vander Hoek Michael |
Chief Financial OfficerOfficer |
• – – |
2022-08-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,095 |
|
- |
|
| Dritschilo Peter |
President and COOOfficer |
• – – |
2022-08-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,380 |
|
- |
|
| Schafer Joshua |
Director |
– • – |
2022-08-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,702 |
|
- |
|
| Richards Steven M |
Director |
– • – |
2022-08-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,702 |
|
- |
|
28 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
